Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Mersana Therapeutics Q4 EPS $(0.11) Beats $(0.15) Estimate, Sales $16.36M Beat $7.71M Estimate

Author: Benzinga Newsdesk | March 03, 2025 08:03am
Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.15) by 26.67 percent. This is a 31.25 percent increase over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $16.36 million which beat the analyst consensus estimate of $7.71 million by 112.20 percent. This is a 52.89 percent increase over sales of $10.70 million the same period last year.

Posted In: MRSN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist